Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2000-08-11
2002-12-31
Eyler, Yvonne (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085100, C424S145100, C514S008100, C514S012200, C514S893000
Reexamination Certificate
active
06500418
ABSTRACT:
BACKGROUND OF THE INVENTION
Crohn's disease persists as an enigma: without a deciphered etiology and without adequate therapy. Prevailing explanations of the pathogenesis of Crohn's disease (Crohn's Disease) hold that the characteristic chronic intestinal inflammation results from an aberrant, activated immune response generated against ubiquitous bacteria or bacterial products that gain access to the lamina propria, perhaps through a more permeable intestinal barrier. The abnormal reaction has been suggested to be mediated principally by T-cells enhanced by an intrinsic imbalance in pro-inflammatory and contra-inflammatory mediators. Thus, most therapy aims to counteract that inflammatory state with increasingly potent and sophisticated immune suppressants.
Current therapy, mostly directed at suppressing the inflammatory process, remains inadequate both for the treatment of flares and maintenance of remission. Steroids can be effective in short term use but produce dependency in a significant proportion of patients. While certain antibiotics appear promising, data are limited. Thus there is a need in the art for effective method for treating inflammatory bowel diseases.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a method of treating Crohn's Disease.
It is an object of the invention to provide a method of treating Ulcerative Colitis.
It is another object of the invention to provide a method of treating extrainstestinal manifestations of Ulcerative Colitis or Crohn's disease.
It is still another object of the invention to provide a method of treating pouchitis.
It is yet another object of the invention to treat and reduce the risk of fistula recurrence.
These and other objects of the invention are provided by one or more of the embodiments described below. In one embodiment a method is provided of treating Crohn's Disease in which an immune stimulatory amount of an agonist of CD114 (Granulocyte Colony Stimulating Factor Receptor (G-CSFR)) is administered to a patient with Crohn's Disease not associated with Glycogen Storage Disease 1b.
In another embodiment of the invention another method of treating Crohn's Disease is provided. An immune stimulatory amount of an agonist of CD 116 (Granulocyte-Macrophage Colony Stimulating Factor Receptor) or CDw131 is administered to a patient with Crohn's Disease not associated with Glycogen Storage Disease 1b.
In yet another embodiment of the invention another method is provided of treating Crohn's Disease. An immune stimulatory amount of an agonist of CD114 (Granulocyte Colony Stimulating Factor Receptor (G-CSFR)) is administered to a patient with Crohn's Disease not associated with Chronic Granulomatous Disease.
In still another embodiment of the invention a method is provided of treating Crohn's Disease in which an immune stimulatory amount of an agonist of CD116 (Granulocyte-Macrophage Colony Stimulating Factor Receptor) or CDw131 is administered to a patient with Crohn's Disease not associated with Chronic Granulomatous Disease.
In even another embodiment of the invention another method is provided of treating Crohn's Disease. An immune stimulatory amount of an agonist of CD114 (Granulocyte Colony Stimulating Factor Receptor (G-CSFR)) is administered to a patient with Crohn's Disease not associated with a presently characterized and identifiable specific neutrophil disorder caused by a genetic disease.
In yet another embodiment of the invention another method is provided of treating Crohn's Disease. An immune stimulatory amount of an agonist of CD116 (Granulocyte-Macrophage Colony Stimulating Factor Receptor) or CDw131 is administered to a patient with Crohn's Disease not associated with a presently characterized and identifiable specific neutrophil disorder caused by a genetic disease.
According to another aspect of the invention a method is provided of treating Ulcerative Colitis. An immune stimulatory amount of an agonist of CD114 (Granulocyte Colony Stimulating Factor Receptor (G-CSFR)) is administered to a patient with Ulcerative Colitis.
According to another aspect of the invention a method is provided of treating Ulcerative Colitis. An immune stimulatory amount of an agonist of CD116 (Granulocyte-Macrophage Colony Stimulating Factor Receptor) or CDw131 is administered to a patient with Ulcerative Colitis.
Another aspect of the invention is a method of treating extraintestinal manifestations of Ulcerative Colitis. An immune stimulatory amount of an agonist of CD114 (Granulocyte Colony Stimulating Factor Receptor (G-CSFR)) is administered to a patient with extraintestinal manifestations of Ulcerative Colitis.
Another aspect of the invention is a method of treating extraintestinal manifestations of Ulcerative Colitis. An immune stimulatory amount of an agonist of CD116 (Granulocyte-Macrophage Colony Stimulating Factor Receptor) or CDw131 is administered to a patient with extraintestinal manifestations of Ulcerative Colitis.
According to still another aspect of the invention a method is provided of treating pouchitis. An immune stimulatory amount of an agonist of CD114 (Granulocyte Colony Stimulating Factor Receptor (G-CSFR)) is administered to a patient with pouchitis.
According to still another aspect of the invention a method is provided of treating pouchitis. An immune stimulatory amount of an agonist of CD116 (Granulocyte-Macrophage Colony Stimulating Factor Receptor) or CDw131 is administered to a patient with pouchitis.
According to still another aspect of the invention a method is provided of preventing or reducing the risk of fistula recurrence. An immune stimulatory amount of an agonist of CD114 (Granulocyte Colony Stimulating Factor Receptor (G-CSFR)) is administered to a patient with Crohn's disease who has previously had a fistula, whereby the risk of recurrence of a fistula is reduced.
According to still another aspect of the invention a method is provided of preventing or reducing the risk of fistula recurrence. An immune stimulatory amount of an agonist of CD116 (Granulocyte-Macrophage Colony Stimulating Factor Receptor) or CDw131 is administered to a patient with Crohn's disease who has previously had a fistula, whereby the risk of recurrence of a fistula is reduced.
The present invention thus opens a new realm of treatment modalities for inflammatory bowel diseases which have proven refractory to discovery of safe and effective ministrations. Contrary to the prior paradigm in the art of treating inflammatory bowel diseases with immunosuppressive agents, the present invention uses agents known to be immunostimulatory to treat, prevent, and maintain remission of such diseases.
REFERENCES:
patent: 4961926 (1990-10-01), Gabrilove
patent: 5284656 (1994-02-01), Platz et al.
patent: 5468846 (1995-11-01), Ichikawa et al.
patent: 5606024 (1997-02-01), Boone et al.
patent: 5654186 (1997-08-01), Cerami
patent: 5762920 (1998-06-01), Yung et al.
patent: 5767156 (1998-06-01), Ferrante et al.
patent: 5790421 (1998-08-01), Osslund
patent: 5814308 (1998-09-01), Zhang
patent: 6020469 (2000-02-01), Hershenson
patent: 6037324 (2000-03-01), Schwender et al.
Roe et al. Treatment of Chronic Inflammatory Disease in Glycogen Storage Diseae Type 1 b with GM-CSF. The NEw England Journal of Medicine. vol. 326, No. 25, pp. 1666-1669, 1992.*
R. Leake, “Molecular Aspects of the GM-CSF Receptor: An Example of the Cell Signalling Mechanisms Used by Type 1 Cytokine Receptors”, European Journal of Cancer, vol. 35, Suppl. 3, pp. S2-S3, 1999.
Dieckgraefe Brian
Korzenik Joshua
Banner & Witcoff , Ltd.
Eyler Yvonne
Hamud Fozia
The Washington University
LandOfFree
Stimulating neutrophil function to treat inflammatory bowel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stimulating neutrophil function to treat inflammatory bowel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stimulating neutrophil function to treat inflammatory bowel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2967445